<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02538666</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-451</org_study_id>
    <secondary_id>2015-002441-61</secondary_id>
    <nct_id>NCT02538666</nct_id>
  </id_info>
  <brief_title>An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy</brief_title>
  <acronym>CheckMate 451</acronym>
  <official_title>A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 451)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, all patients must have already completed first-line chemotherapy to treat
      extensive-stage disease small cell lung cancer. The purpose of this study is to show that
      nivolumab, or nivolumab plus ipilimumab followed by nivolumab by itself, will prolong overall
      survival when administered as consolidation treatment in patients that are stable or
      responding after chemotherapy. Patients receiving treatment will be compared with patients
      taking placebo.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 30, 2015</start_date>
  <completion_date type="Anticipated">February 13, 2021</completion_date>
  <primary_completion_date type="Actual">October 1, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS) of Nivo + Ipi vs Placebo</measure>
    <time_frame>Approximately 37 months after the first subject is randomized</time_frame>
    <description>OS was defined as the time from randomization to the date of death. A participant who had not died was censored at last known alive date. OS was followed up during the blinded study drug treatment and every 3 months via in-person or phone contact after participant discontinued the blinded study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Approximately 37 months after the first subject is randomized</time_frame>
    <description>OS was defined as the time from randomization to the date of death. A participant who had not died was censored at last known alive date. OS was followed up during the blinded study drug treatment and every 3 months via in-person or phone contact after participant discontinued the blinded study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Approximately 37 months after the first subject is randomized</time_frame>
    <description>PFS (primary definition) was defined as the time between the date of randomization and the first date of documented progression as determined by Blind Independent Central Review (BICR) or death due to any cause, whichever occurred first. Participants who died with no reported progression were considered to have progressed on the date of death. Participants who did not progress or die were censored on the date of their last evaluable tumor assessment on or prior to initiation of the subsequent anti-cancer therapy. Participants who did not have any on study tumor assessments and did not die (or died after initiation of the subsequent anti- cancer therapy) were censored on their date of randomization. Participants who started any subsequent anti- cancer therapy without a prior reported Progressive Disease (PD) per BICR were censored at the last evaluable tumor assessment on or prior to initiation of the subsequent anti-cancer therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS in TMB High and Low Subgroups by TMB Cutoff</measure>
    <time_frame>Approximately 37 Months</time_frame>
    <description>OS in TMB by the following cutoff points: ≥10 mutations/mb, &lt; 10 mutations/mb, ≥13 mutations/mb, &lt;13 mutations/mb</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS in TMB High and Low Subgroups by TMB Cutoff</measure>
    <time_frame>Approximately 37 Months</time_frame>
    <description>PFS in TMB by the following cutoff points: ≥10 mutations/mb, &lt; 10 mutations/mb, ≥13 mutations/mb, &lt;13 mutations/mb</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1212</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Nivolumab monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab intravenous fusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab and ipilimumab combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab and ipilimumab intravenous fusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <arm_group_label>Nivolumab and ipilimumab combination therapy</arm_group_label>
    <arm_group_label>Nivolumab monotherapy</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <arm_group_label>Nivolumab and ipilimumab combination therapy</arm_group_label>
    <other_name>Yervoy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Subjects with histologically or cytologically confirmed extensive stage disease SCLC

          -  Ongoing response of stable disease or better following 4 cycles of platinum-based
             first line chemotherapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

        Exclusion Criteria:

          -  Subjects with symptomatic Central Nervous System (CNS) metastases

          -  Subjects receiving consolidative chest radiation

          -  Subjects with active, known, or suspected autoimmune disease are excluded

          -  All side effects attributed to prior anti-cancer therapy must have resolved to Grade 1
             or baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sutter Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists S.</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists of North FL</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscan St. Francis Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center - Clinical Research Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center Of Kansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Health Lexington</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novant Health Oncology Specialists</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Health</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Health Network</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Donald Guthrie Foundation</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Health</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Institute</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berazategui</city>
        <state>Buenos Aires</state>
        <zip>1880</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>1426</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ciudad Autonoma De Buenos Aire</city>
        <state>Buenos Aires</state>
        <zip>1181</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cordoba</city>
        <zip>5004</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tucuman</city>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Birtinya</city>
        <state>Queensland</state>
        <zip>4575</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3165</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wien</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceara</state>
        <zip>60430-230</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30110-022</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ijui</city>
        <state>RIO Grande DO SUL</state>
        <zip>98700-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Porto Alegre</city>
        <state>RIO Grande DO SUL</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Itajai</city>
        <state>Santa Catarina</state>
        <zip>88301-220</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barretos</city>
        <state>SAO Paulo</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22793-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Salvador</city>
        <zip>40170-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 2X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>155040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wuhang</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nantong</city>
        <state>Jiangsu</state>
        <zip>226361</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110046</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650118</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guangzhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Monteria</city>
        <state>Cordoba</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Medellin</city>
        <zip>MEDELLIN</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Oulu</city>
        <zip>90029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Turku</city>
        <zip>FIN-20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vaasa</city>
        <zip>65130</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Avignon Cedes 9</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lyon Cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Marseille Cedex 20</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris Cedex 20</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rennes Cedex 9</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nouvel Hopital Civil Chru De Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67090</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bad Berka</city>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berlin</city>
        <zip>14165</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gauting</city>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Immenhausen</city>
        <zip>34376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Oncology Hospital of Kifissia Agioi Anargyroi</name>
      <address>
        <city>N.Kifissia</city>
        <zip>14564</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interbalkan European Medical Center</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57001</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wilton</city>
        <state>Cork</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dublin</city>
        <zip>24</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dublin</city>
        <zip>4</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Galway</city>
        <zip>ST4 6QG</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Limerick</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zerifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Messina</city>
        <zip>98158</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Perugia</city>
        <zip>06132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>2778577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Matsuyama-shi</city>
        <state>Ehime</state>
        <zip>7910280</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>8128582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kurume-shi</city>
        <state>Fukuoka</state>
        <zip>8300011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gifu-shi</city>
        <state>Gifu</state>
        <zip>5008513</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>0608648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <zip>6500047</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kanazawa-shi</city>
        <state>Ishikawa</state>
        <zip>9208641</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <zip>2408555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <zip>9800873</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <zip>9808574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kurashiki-shi</city>
        <state>Okayama</state>
        <zip>7108602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hirakata-shi</city>
        <state>Osaka</state>
        <zip>5731191</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Osaka-sayama-shi</city>
        <state>Osaka</state>
        <zip>5898511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>5340021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Takatsuki-shi</city>
        <state>Osaka</state>
        <zip>5698686</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hidaka-shi</city>
        <state>Saitama</state>
        <zip>3501298</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>1130022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>1040045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <zip>1358550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>1600023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wakayama-shi</city>
        <state>Wakayama</state>
        <zip>6418510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggi-do</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Leon de los Aldama</city>
        <state>Guanajuato</state>
        <zip>37000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo LEON</state>
        <zip>64000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Queretaro</city>
        <zip>76090</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <zip>5223 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Miraflores</city>
        <state>Lima</state>
        <zip>18</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lima</city>
        <zip>27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lima</city>
        <zip>34</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gdansk</city>
        <zip>80-19</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gdynia</city>
        <zip>81-519</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-357</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bucharest</city>
        <zip>010991</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bucharest</city>
        <zip>020122</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Craiova</city>
        <zip>200347</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lasi</city>
        <zip>700106</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Romania</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Timisoara, Timis</city>
        <zip>300239</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>105229</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>121309</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St Petersburg</city>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sandton</city>
        <state>Gauteng</state>
        <zip>2199</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cape Town</city>
        <state>Western CAPE</state>
        <zip>7570</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cape Town</city>
        <state>Western CAPE</state>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>George</city>
        <state>Western CAPE</state>
        <zip>6530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Aarau</city>
        <zip>5000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Geneve</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Truro</city>
        <state>Cornwall</state>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wirral</city>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 26, 2015</study_first_submitted>
  <study_first_submitted_qc>September 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2015</study_first_posted>
  <results_first_submitted>October 1, 2019</results_first_submitted>
  <results_first_submitted_qc>October 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2019</results_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT02538666/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT02538666/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>1212 participants enrolled; 834 randomized. 378 Not Randomized. Reasons not randomized: 2 Adverse events, 31 withdrew consent, 2 lost to follow up, 3 poor/non-compliant, 334 no longer met study criteria, 5 not reported, 1 other therapy was proposed</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo (Pbo)</title>
          <description>Nivo pbo: 100 mL and Ipi pbo: 100 mL</description>
        </group>
        <group group_id="P2">
          <title>Nivolumab</title>
          <description>nivolumab 240mg Q2W IV infusion</description>
        </group>
        <group group_id="P3">
          <title>Nivolumab + Ipilimumab</title>
          <description>nivolumab 1mg/kg IV + ipilimumab 3mg/kg IV Q3W for Four (4) doses followed by nivolumab 240mg Q2W</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="275"/>
                <participants group_id="P2" count="280"/>
                <participants group_id="P3" count="279"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="273"/>
                <participants group_id="P2" count="279"/>
                <participants group_id="P3" count="278"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>no longer meets study criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All Randomized Participants</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo (Pbo)</title>
          <description>Nivo pbo: 100 mL and Ipi pbo: 100 mL</description>
        </group>
        <group group_id="B2">
          <title>Nivolumab</title>
          <description>nivolumab 240mg Q2W IV infusion</description>
        </group>
        <group group_id="B3">
          <title>Nivolumab + Ipilimumab</title>
          <description>nivolumab 1mg/kg IV + ipilimumab 3mg/kg IV Q3W for Four (4) doses followed by nivolumab 240mg Q2W</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="275"/>
            <count group_id="B2" value="280"/>
            <count group_id="B3" value="279"/>
            <count group_id="B4" value="834"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.2" spread="8.1"/>
                    <measurement group_id="B2" value="64.6" spread="8.6"/>
                    <measurement group_id="B3" value="63.9" spread="8.8"/>
                    <measurement group_id="B4" value="63.9" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="302"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="175"/>
                    <measurement group_id="B2" value="177"/>
                    <measurement group_id="B3" value="180"/>
                    <measurement group_id="B4" value="532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="164"/>
                    <measurement group_id="B4" value="474"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="213"/>
                    <measurement group_id="B3" value="216"/>
                    <measurement group_id="B4" value="627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS) of Nivo + Ipi vs Placebo</title>
        <description>OS was defined as the time from randomization to the date of death. A participant who had not died was censored at last known alive date. OS was followed up during the blinded study drug treatment and every 3 months via in-person or phone contact after participant discontinued the blinded study drug</description>
        <time_frame>Approximately 37 months after the first subject is randomized</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Nivo pbo: 100 mL and Ipi pbo: 100 mL</description>
          </group>
          <group group_id="O2">
            <title>Nivolumab + Ipilimumab</title>
            <description>nivolumab 1mg/kg IV + ipilimumab 3mg/kg IV Q3W for Four (4) doses followed by nivolumab 240mg Q2W</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) of Nivo + Ipi vs Placebo</title>
          <description>OS was defined as the time from randomization to the date of death. A participant who had not died was censored at last known alive date. OS was followed up during the blinded study drug treatment and every 3 months via in-person or phone contact after participant discontinued the blinded study drug</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.56" lower_limit="8.18" upper_limit="11.01"/>
                    <measurement group_id="O2" value="9.17" lower_limit="8.15" upper_limit="10.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>nivo + ipi over placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3693</p_value>
            <method>Stratified Log Rank</method>
            <method_desc>Stratified by response to ECOG PS (0vs1), gender (MvF), irradiation following chemotherapy (YorN) as entered in IVRS</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>based on stratified 3-arms Cox proportional hazard model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS was defined as the time from randomization to the date of death. A participant who had not died was censored at last known alive date. OS was followed up during the blinded study drug treatment and every 3 months via in-person or phone contact after participant discontinued the blinded study drug</description>
        <time_frame>Approximately 37 months after the first subject is randomized</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Nivo pbo: 100 mL and Ipi pbo: 100 mL</description>
          </group>
          <group group_id="O2">
            <title>Nivolumab</title>
            <description>nivolumab 240mg Q2W IV infusion</description>
          </group>
          <group group_id="O3">
            <title>Nivolumab + Ipilimumab</title>
            <description>nivolumab 1mg/kg IV + ipilimumab 3mg/kg IV Q3W for Four (4) doses followed by nivolumab 240mg Q2W</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS was defined as the time from randomization to the date of death. A participant who had not died was censored at last known alive date. OS was followed up during the blinded study drug treatment and every 3 months via in-person or phone contact after participant discontinued the blinded study drug</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="280"/>
                <count group_id="O3" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.56" lower_limit="8.18" upper_limit="11.01"/>
                    <measurement group_id="O2" value="10.41" lower_limit="9.46" upper_limit="12.12"/>
                    <measurement group_id="O3" value="9.17" lower_limit="8.15" upper_limit="10.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>nivo over placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>based on stratified 3-arms Cox proportional hazard model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>nivo + ipi over nivo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
            <estimate_desc>Hazard Ratios are based on stratified 3-arms Cox proportional hazard model.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>PFS (primary definition) was defined as the time between the date of randomization and the first date of documented progression as determined by Blind Independent Central Review (BICR) or death due to any cause, whichever occurred first. Participants who died with no reported progression were considered to have progressed on the date of death. Participants who did not progress or die were censored on the date of their last evaluable tumor assessment on or prior to initiation of the subsequent anti-cancer therapy. Participants who did not have any on study tumor assessments and did not die (or died after initiation of the subsequent anti- cancer therapy) were censored on their date of randomization. Participants who started any subsequent anti- cancer therapy without a prior reported Progressive Disease (PD) per BICR were censored at the last evaluable tumor assessment on or prior to initiation of the subsequent anti-cancer therapy.</description>
        <time_frame>Approximately 37 months after the first subject is randomized</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Nivo pbo: 100 mL and Ipi pbo: 100 mL</description>
          </group>
          <group group_id="O2">
            <title>Nivolumab</title>
            <description>nivolumab 240mg Q2W IV infusion</description>
          </group>
          <group group_id="O3">
            <title>Nivolumab + Ipilimumab</title>
            <description>nivolumab 1mg/kg IV + ipilimumab 3mg/kg IV Q3W for Four (4) doses followed by nivolumab 240mg Q2W</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>PFS (primary definition) was defined as the time between the date of randomization and the first date of documented progression as determined by Blind Independent Central Review (BICR) or death due to any cause, whichever occurred first. Participants who died with no reported progression were considered to have progressed on the date of death. Participants who did not progress or die were censored on the date of their last evaluable tumor assessment on or prior to initiation of the subsequent anti-cancer therapy. Participants who did not have any on study tumor assessments and did not die (or died after initiation of the subsequent anti- cancer therapy) were censored on their date of randomization. Participants who started any subsequent anti- cancer therapy without a prior reported Progressive Disease (PD) per BICR were censored at the last evaluable tumor assessment on or prior to initiation of the subsequent anti-cancer therapy.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="280"/>
                <count group_id="O3" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" lower_limit="1.41" upper_limit="1.48"/>
                    <measurement group_id="O2" value="1.87" lower_limit="1.61" upper_limit="2.63"/>
                    <measurement group_id="O3" value="1.74" lower_limit="1.48" upper_limit="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>nivo + ipi over placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
            <estimate_desc>Hazard Ratios based on stratified 3-arms Cox proportional hazard model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>nivo over placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>0.81</ci_upper_limit>
            <estimate_desc>Hazard Ratios based on stratified 3-arms Cox proportional hazard model</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>nivo+ ipi over nivo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
            <estimate_desc>Hazard Ratios are based on stratified 3-arms Cox proportional hazard model.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS in TMB High and Low Subgroups by TMB Cutoff</title>
        <description>OS in TMB by the following cutoff points: ≥10 mutations/mb, &lt; 10 mutations/mb, ≥13 mutations/mb, &lt;13 mutations/mb</description>
        <time_frame>Approximately 37 Months</time_frame>
        <population>All TMB Evaluable Participants, Global Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Nivo pbo: 100 mL and Ipi pbo: 100 mL</description>
          </group>
          <group group_id="O2">
            <title>Nivolumab</title>
            <description>nivolumab 240mg Q2W IV infusion</description>
          </group>
          <group group_id="O3">
            <title>Nivolumab + Ipilimumab</title>
            <description>nivolumab 1mg/kg IV + ipilimumab 3mg/kg IV Q3W for Four (4) doses followed by nivolumab 240mg Q2W</description>
          </group>
        </group_list>
        <measure>
          <title>OS in TMB High and Low Subgroups by TMB Cutoff</title>
          <description>OS in TMB by the following cutoff points: ≥10 mutations/mb, &lt; 10 mutations/mb, ≥13 mutations/mb, &lt;13 mutations/mb</description>
          <population>All TMB Evaluable Participants, Global Population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="196"/>
                <count group_id="O3" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥10 mutations/mb</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.50" lower_limit="7.49" upper_limit="13.63"/>
                    <measurement group_id="O2" value="12.98" lower_limit="10.02" upper_limit="17.91"/>
                    <measurement group_id="O3" value="10.55" lower_limit="8.38" upper_limit="14.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 10 mutations/mb</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.20" lower_limit="7.46" upper_limit="11.04"/>
                    <measurement group_id="O2" value="9.89" lower_limit="8.34" upper_limit="11.30"/>
                    <measurement group_id="O3" value="8.11" lower_limit="6.60" upper_limit="10.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥13 mutations/mb</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.53" lower_limit="6.21" upper_limit="13.54"/>
                    <measurement group_id="O2" value="13.24" lower_limit="10.02" upper_limit="17.91"/>
                    <measurement group_id="O3" value="13.47" lower_limit="9.26" upper_limit="21.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;13 mutations/mb</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="125"/>
                    <count group_id="O3" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.02" lower_limit="7.66" upper_limit="11.47"/>
                    <measurement group_id="O2" value="10.09" lower_limit="8.67" upper_limit="11.30"/>
                    <measurement group_id="O3" value="7.85" lower_limit="6.67" upper_limit="9.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>TMB cutoff ≥10 mutations/mb: Nivo+Ipi over placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>Unstratified Cox proportional hazard model. Hazard Ratios are experimental treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>TMB cutoff ≥10 mutations/mb: Nivo over placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>Unstratified Cox proportional hazard model. Hazard Ratios are experimental treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>TMB cutoff ≥13 mutations/mb: Nivo+Ipi over placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
            <estimate_desc>Unstratified Cox proportional hazard model. Hazard Ratios are experimental treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>TMB cutoff ≥13 mutations/mb: Nivo over placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>Unstratified Cox proportional hazard model. Hazard Ratios are experimental treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>TMB cutoff &lt;10 mutations/mb: Nivo+Ipi over placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
            <estimate_desc>Unstratified Cox proportional hazard model. Hazard Ratios are experimental treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>TMB cutoff &lt;10 mutations/mb: Nivo over placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
            <estimate_desc>Unstratified Cox proportional hazard model. Hazard Ratios are experimental treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>TMB cutoff &lt;13 mutations/mb: Nivo+Ipi over placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
            <estimate_desc>Unstratified Cox proportional hazard model. Hazard Ratios are experimental treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>TMB cutoff &lt;13 mutations/mb: Nivo over placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
            <estimate_desc>Unstratified Cox proportional hazard model. Hazard Ratios are experimental treatment group over placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS in TMB High and Low Subgroups by TMB Cutoff</title>
        <description>PFS in TMB by the following cutoff points: ≥10 mutations/mb, &lt; 10 mutations/mb, ≥13 mutations/mb, &lt;13 mutations/mb</description>
        <time_frame>Approximately 37 Months</time_frame>
        <population>All TMB Evaluable Participants, Global Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Nivo pbo: 100 mL and Ipi pbo: 100 mL</description>
          </group>
          <group group_id="O2">
            <title>Nivolumab</title>
            <description>nivolumab 240mg Q2W IV infusion</description>
          </group>
          <group group_id="O3">
            <title>Nivolumab + Ipilimumab</title>
            <description>nivolumab 1mg/kg IV + ipilimumab 3mg/kg IV Q3W for Four (4) doses followed by nivolumab 240mg Q2W</description>
          </group>
        </group_list>
        <measure>
          <title>PFS in TMB High and Low Subgroups by TMB Cutoff</title>
          <description>PFS in TMB by the following cutoff points: ≥10 mutations/mb, &lt; 10 mutations/mb, ≥13 mutations/mb, &lt;13 mutations/mb</description>
          <population>All TMB Evaluable Participants, Global Population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="196"/>
                <count group_id="O3" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥10 mutations/mb</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" lower_limit="1.41" upper_limit="2.63"/>
                    <measurement group_id="O2" value="2.79" lower_limit="2.10" upper_limit="4.17"/>
                    <measurement group_id="O3" value="2.33" lower_limit="1.48" upper_limit="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 10 mutations/mb</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" lower_limit="1.35" upper_limit="1.45"/>
                    <measurement group_id="O2" value="1.61" lower_limit="1.45" upper_limit="2.27"/>
                    <measurement group_id="O3" value="1.48" lower_limit="1.41" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥13 mutations/mb</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" lower_limit="1.41" upper_limit="2.63"/>
                    <measurement group_id="O2" value="2.76" lower_limit="1.64" upper_limit="4.11"/>
                    <measurement group_id="O3" value="2.66" lower_limit="1.48" upper_limit="3.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;13 mutations/mb</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="125"/>
                    <count group_id="O3" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" lower_limit="1.38" upper_limit="1.45"/>
                    <measurement group_id="O2" value="1.61" lower_limit="1.45" upper_limit="2.56"/>
                    <measurement group_id="O3" value="1.48" lower_limit="1.41" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>TMB cutoff ≥10 mutations/mb: Nivo+Ipi over placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>Unstratified Cox proportional hazard model. Hazard Ratios are experimental treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>TMB cutoff ≥10 mutations/mb: Nivo over placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
            <estimate_desc>Unstratified Cox proportional hazard model. Hazard Ratios are experimental treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>TMB cutoff ≥13 mutations/mb: Nivo+Ipi over placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>Unstratified Cox proportional hazard model. Hazard Ratios are experimental treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>TMB cutoff ≥13 mutations/mb: Nivo over placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
            <estimate_desc>Unstratified Cox proportional hazard model. Hazard Ratios are experimental treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>TMB cutoff &lt;10 mutations/mb: Nivo+Ipi over placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
            <estimate_desc>Unstratified Cox proportional hazard model. Hazard Ratios are experimental treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>TMB cutoff &lt;10 mutations/mb: Nivo over placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
            <estimate_desc>Unstratified Cox proportional hazard model. Hazard Ratios are experimental treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>TMB cutoff &lt;13 mutations/mb: Nivo+Ipi over placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>Unstratified Cox proportional hazard model. Hazard Ratios are experimental treatment group over placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>TMB cutoff &lt;13 mutations/mb: Nivo over placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
            <estimate_desc>Unstratified Cox proportional hazard model. Hazard Ratios are experimental treatment group over placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Reporting Adverse Events (AEs) include events reported between first dose and 30 days after last dose of study therapy</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Nivo pbo: 100 mL and Ipi pbo: 100 mL</description>
        </group>
        <group group_id="E2">
          <title>Nivolumab 240 mg</title>
          <description>nivolumab 240mg Q2W IV infusion</description>
        </group>
        <group group_id="E3">
          <title>Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg</title>
          <description>nivolumab 1mg/kg IV + ipilimumab 3mg/kg IV Q3W for Four (4) doses followed by nivolumab 240mg Q2W</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="210" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="194" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="189" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="165" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Addison's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Adrenocortical insufficiency acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Cushing's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Hypopituitarism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Papilloedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Rhegmatogenous retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Autoimmune colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Enterocolitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Pancreatic mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Proctitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Performance status decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Immune-mediated hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Gastric infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Infective thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Vascular device infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Appetite disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Spinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Metastases to spinal cord</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Encephalitis autoimmune</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Limbic encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Neurological symptom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Occipital neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Bladder mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Renal tubular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Alveolitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Bronchial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Skin toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Subcutaneous emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Superior vena cava stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Superior vena cava syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="218" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="235" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="260" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="83" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="96" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="278"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="273"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="279"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="278"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <phone>Please Email</phone>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

